Developer docs
API playgroundTry for free, no card

Search company profiles

Prolaio

Full company profile

uuid0000eec

Namestring
Prolaio
Legal namestring
Prolaio Inc.
Websiteurl
prolaio.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Prolaio is a cardiovascular clinical intelligence company that develops an AI-based platform integrating wearable sensor data with proprietary analytics to support pharmaceutical and biotech clinical development. Its core product, the Prolaio Clinical Intelligence Platform, continuously collects high-density data — including ECG, pulse, respiration, and activity — from clinical-grade wearables and applies FDA-cleared algorithms, including the eVO2peak cardiopulmonary measure and a Digital Twin personalization engine, to generate cardiovascular function insights correlated with standard clinical assessments. The company also operates the OCORO Heart Study, a national, all-remote observational study enrolling US adults with diagnosed heart conditions for up to five years of longitudinal monitoring.

The company serves three customer segments: pharmaceutical and biotech sponsors running cardiovascular trials (primary segment), healthcare providers and cardiologists using remote patient monitoring, and individual patients contributing data through the OCORO study. Its revenue model is enterprise sales-led, with subscription/recurring clinical research services for sponsors, platform licensing for researchers, and data and analytics licensing arrangements. The company has accumulated 4M+ hours of on-body patient data across 22+ countries, holds 20+ issued patents, and operates under 7 FDA-cleared algorithms alongside ISO 13485:2016 and MDSAP certifications.

In November 2025 Prolaio was acquired by Kardigan, a cardiovascular therapeutics company also co-founded by Tassos Gianakakos. The acquisition integrates Prolaio's clinical intelligence platform and CV data asset with Kardigan's three late-stage drug programs, positioning the combined entity to embed continuous real-world data and AI-driven patient identification across the drug-development lifecycle. Headquartered in Chicago, IL with 11-50 employees, Prolaio continues to operate the OCORO Heart Study and clinical research services under the Kardigan umbrella.

Short descriptiontext

Prolaio is a cardiovascular clinical intelligence company that uses FDA-cleared AI algorithms and continuous wearable monitoring to provide pharma/biotech sponsors, healthcare providers, and patients with real-world heart data and clinical research services, now operating under Kardigan following its November 2025 acquisition.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersChicago, United States
HQ citystring
Chicago
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiovascular clinical trials, remote patient monitoring, wearable cardiac monitoring, clinical intelligence platform, digital health analytics
Industry4 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLALAGAB
Cardiology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLAKABAF
Preventive Cardiology & Lipidology
SECONDARYHLAGAAAJ
Imaging & Cardiac Safety Core Labs (ECOG/EEG/ECG)
NAICS code2 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Medical and Diagnostic Laboratories62151
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Cardiovascular Clinical Intelligence Platform
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Clinical Research Services
TypeSubscription Recurring
Description

Prolaio provides clinical intelligence services to pharmaceutical and biotech companies conducting cardiovascular clinical trials, enabling patient identification, enrollment optimization, and continuous data collection throughout trial intervals.

prolaio.com
2Platform Access for Researchers
TypeSubscription Recurring
Description

Licensing of the Prolaio platform to clinical researchers for longitudinal data collection, real-world evidence generation, and trial optimization.

prolaio.com
3Data and Analytics Licensing
TypeLicensing Royalties
Description

Access to Prolaio's extensive cardiovascular data set and advanced analytics to enhance drug development processes, as demonstrated by the Kardigan acquisition.

biospace.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1OCORO Heart Study
Description

A national, observational heart study designed to help researchers understand how heart conditions behave over time, using wearable devices and secure digital tools.

prolaio.com
+1 more record
Core offering1 text field

Prolaio provides a cardiovascular clinical intelligence platform that integrates continuous high-density data from clinical-grade wearable sensors with proprietary AI-based algorithms. The platform supports pharmaceutical and biotech companies conducting cardiovascular clinical trials through patient identification, enrollment optimization, real-world evidence generation, and predictive analytics. Key capabilities include FDA-cleared algorithms such as eVO2peak and a Digital Twin machine-learning technology for predicting heart-failure decompensation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Detection of impending heart-failure decompensation approximately 6.5 days before symptom onset
+1 more record
Product overview1 text field

Prolaio is a cardiovascular clinical intelligence company offering a unified platform combining continuous wearable monitoring, AI-powered analytics, and clinical research services. The core Prolaio Clinical Intelligence Platform integrates medical insights and data analytics designed to improve cardiovascular clinical development. The company operates the OCORO Heart Study, a national observational registry that collects continuous cardiovascular data from participants using wearable devices including ECG patches and CardioWatch. Key technology offerings include eVO2peak, an FDA-cleared algorithm for remote cardiopulmonary assessment, and Digital Twin machine learning technology for predicting heart failure decompensation. The platform collects over 4 million hours of on-body patient data across 22+ countries, powered by 20+ issued patents and 7 FDA-cleared algorithms.

Product and service1 record
1Prolaio Clinical Intelligence Platform
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-11-01
Description

Kardigan acquired Prolaio in November 2025 to create a pioneering heart health company with integrated cardiovascular data and therapeutics platform. The acquisition grants Kardigan access to Prolaio's extensive CV data set and advanced analytics to improve patient identification and trial enrollment for its three late-stage cardiovascular drug programs. Tassos Gianakakos, co-founder of both companies, leads the combined entity. Note: This is an acquisition relationship where Prolaio became part of Kardigan.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

iRhythm's Zio long-term continuous ECG monitoring patch and AI-backed arrhythmia detection compete head-to-head with Prolaio's ECG patch-based continuous monitoring platform. Both serve clinicians and clinical trial sponsors with wearable cardiac monitoring and analytics.

TypeDirect peer
Description

AliveCor offers consumer and clinical ECG products (KardiaMobile) with AI-based cardiac arrhythmia detection, overlapping with Prolaio's continuous ECG and AI analytics approach for cardiovascular monitoring.

TypeDirect peer
Description

Eko combines digital stethoscopes with AI-based cardiac analysis (including FDA-cleared algorithms) for clinicians and clinical research, mirroring Prolaio's combination of FDA-cleared algorithms and continuous cardiac data capture.

TypeDirect peer
Description

HeartFlow applies AI to cardiovascular imaging and analytics for clinical decision support and is sold into cardiology workflows. Like Prolaio, it is an AI-driven cardiovascular clinical intelligence company with FDA-cleared technology.

TypeBroad incumbent
Description

Preventice, now part of Boston Scientific, provides ambulatory ECG and cardiac monitoring services, competing with Prolaio's wearable-based continuous monitoring but operating as part of a much larger device and services portfolio.

TypeBroad incumbent
Description

Philips offers cardiac monitoring, ECG, and clinical research services through its connected care and BioTel heritage businesses. It competes with Prolaio in continuous ambulatory monitoring and clinical trial support, but as one segment within a broad medtech portfolio.

7Tempus Labs
TypeBroad incumbent
Description

Tempus provides AI-driven precision medicine data and analytics infrastructure to pharma and providers, including for clinical trial design and real-world evidence. It overlaps with Prolaio's platform as a clinical intelligence layer for pharma-sponsored research, though across multiple therapeutic areas.

TypeBroad incumbent
Description

Verily builds clinical research platforms, wearable sensors, and real-world evidence infrastructure for life sciences companies. It competes with Prolaio in continuous wearable data and clinical trial analytics, backed by Alphabet-scale resources.

TypeEmerging player
Description

CardioSignal develops smartphone- and wearable-based AI analytics for cardiac function, with overlapping technology approach to Prolaio's continuous monitoring and Digital Twin-style analytics, though earlier stage and more consumer-facing.

TypeBroad incumbent
Description

Bardy Diagnostics (acquired by Hillrom, now part of Baxter) developed the CAM patch for continuous ambulatory ECG, directly overlapping with Prolaio's ECG patch-based continuous monitoring technology.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Prolaio

Cardiovascular Clinical Intelligence Platformprolaio.com

Prolaio is a cardiovascular clinical intelligence company that uses FDA-cleared AI algorithms and continuous wearable monitoring to provide pharma/biotech sponsors, healthcare providers, and patients with real-world heart data and clinical research services, now operating under Kardigan following its November 2025 acquisition.

What Prolaio does

Prolaio is a cardiovascular clinical intelligence company that develops an AI-based platform integrating wearable sensor data with proprietary analytics to support pharmaceutical and biotech clinical development. Its core product, the Prolaio Clinical Intelligence Platform, continuously collects high-density data — including ECG, pulse, respiration, and activity — from clinical-grade wearables and applies FDA-cleared algorithms, including the eVO2peak cardiopulmonary measure and a Digital Twin personalization engine, to generate cardiovascular function insights correlated with standard clinical assessments. The company also operates the OCORO Heart Study, a national, all-remote observational study enrolling US adults with diagnosed heart conditions for up to five years of longitudinal monitoring.

The company serves three customer segments: pharmaceutical and biotech sponsors running cardiovascular trials (primary segment), healthcare providers and cardiologists using remote patient monitoring, and individual patients contributing data through the OCORO study. Its revenue model is enterprise sales-led, with subscription/recurring clinical research services for sponsors, platform licensing for researchers, and data and analytics licensing arrangements. The company has accumulated 4M+ hours of on-body patient data across 22+ countries, holds 20+ issued patents, and operates under 7 FDA-cleared algorithms alongside ISO 13485:2016 and MDSAP certifications.

In November 2025 Prolaio was acquired by Kardigan, a cardiovascular therapeutics company also co-founded by Tassos Gianakakos. The acquisition integrates Prolaio's clinical intelligence platform and CV data asset with Kardigan's three late-stage drug programs, positioning the combined entity to embed continuous real-world data and AI-driven patient identification across the drug-development lifecycle. Headquartered in Chicago, IL with 11-50 employees, Prolaio continues to operate the OCORO Heart Study and clinical research services under the Kardigan umbrella.

Prolaio firmographics

Firmographics
Name
Prolaio
Legal name
Prolaio Inc.
Website
https://prolaio.com
Company type
Private
Founded year
2022
Operating status
Acquired
Headcount range
51–100 employees
Short description
Prolaio is a cardiovascular clinical intelligence company that uses FDA-cleared AI algorithms and continuous wearable monitoring to provide pharma/biotech sponsors, healthcare providers, and patients with real-world heart data and clinical research services, now operating under Kardigan following its November 2025 acquisition.
Ownership category
akta.pro rank

Prolaio industry classification

Industry
Product category
Cardiovascular Clinical Intelligence Platform
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Medical and Diagnostic Laboratories (62151)
SIC
Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLALAGAB
Cardiology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLAKABAF
Preventive Cardiology & Lipidology
SECONDARYHLAGAAAJ
Imaging & Cardiac Safety Core Labs (ECOG/EEG/ECG)

Keywords

  • Cardiovascular clinical trials
  • Remote patient monitoring
  • Wearable cardiac monitoring
  • Clinical intelligence platform
  • Digital health analytics

Where Prolaio is headquartered

Location

Headquarters

HQ city
Chicago
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Prolaio business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Clinical Research Services: Prolaio provides clinical intelligence services to pharmaceutical and biotech companies conducting cardiovascular clinical trials, enabling patient identification, enrollment optimization, and continuous data collection throughout trial intervals.
  2. Platform Access for Researchers: Licensing of the Prolaio platform to clinical researchers for longitudinal data collection, real-world evidence generation, and trial optimization.
  3. Data and Analytics Licensing: Access to Prolaio's extensive cardiovascular data set and advanced analytics to enhance drug development processes, as demonstrated by the Kardigan acquisition.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Prolaio product offering

Product offering

Core offering

Prolaio provides a cardiovascular clinical intelligence platform that integrates continuous high-density data from clinical-grade wearable sensors with proprietary AI-based algorithms. The platform supports pharmaceutical and biotech companies conducting cardiovascular clinical trials through patient identification, enrollment optimization, real-world evidence generation, and predictive analytics. Key capabilities include FDA-cleared algorithms such as eVO2peak and a Digital Twin machine-learning technology for predicting heart-failure decompensation.

Product overview

Prolaio is a cardiovascular clinical intelligence company offering a unified platform combining continuous wearable monitoring, AI-powered analytics, and clinical research services. The core Prolaio Clinical Intelligence Platform integrates medical insights and data analytics designed to improve cardiovascular clinical development. The company operates the OCORO Heart Study, a national observational registry that collects continuous cardiovascular data from participants using wearable devices including ECG patches and CardioWatch. Key technology offerings include eVO2peak, an FDA-cleared algorithm for remote cardiopulmonary assessment, and Digital Twin machine learning technology for predicting heart failure decompensation. The platform collects over 4 million hours of on-body patient data across 22+ countries, powered by 20+ issued patents and 7 FDA-cleared algorithms.

Differentiator

Problem solved

Functional benefit

Brands

  • OCORO Heart Study: A national, observational heart study designed to help researchers understand how heart conditions behave over time, using wearable devices and secure digital tools.
  • eVO2peak

Products and services

  • Prolaio Clinical Intelligence Platform

Quantifiable outcome

  • Detection of impending heart-failure decompensation approximately 6.5 days before symptom onset
  • +1 more outcomes

Companies that use Prolaio

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Prolaio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Prolaio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • KardiganflagshipStrategic or Co-development Partner · 1 November 2025Kardigan acquired Prolaio in November 2025 to create a pioneering heart health company with integrated cardiovascular data and therapeutics platform. The acquisition grants Kardigan access to Prolaio's extensive CV data set and advanced analytics to improve patient identification and trial enrollment for its three late-stage cardiovascular drug programs. Tassos Gianakakos, co-founder of both companies, leads the combined entity. Note: This is an acquisition relationship where Prolaio became part of Kardigan.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Prolaio competitors and assessment

Company assessment

Direct peers

  • iRhythm Technologies: iRhythm's Zio long-term continuous ECG monitoring patch and AI-backed arrhythmia detection compete head-to-head with Prolaio's ECG patch-based continuous monitoring platform. Both serve clinicians and clinical trial sponsors with wearable cardiac monitoring and analytics.
  • AliveCor: AliveCor offers consumer and clinical ECG products (KardiaMobile) with AI-based cardiac arrhythmia detection, overlapping with Prolaio's continuous ECG and AI analytics approach for cardiovascular monitoring.
  • Eko Health: Eko combines digital stethoscopes with AI-based cardiac analysis (including FDA-cleared algorithms) for clinicians and clinical research, mirroring Prolaio's combination of FDA-cleared algorithms and continuous cardiac data capture.
  • HeartFlow: HeartFlow applies AI to cardiovascular imaging and analytics for clinical decision support and is sold into cardiology workflows. Like Prolaio, it is an AI-driven cardiovascular clinical intelligence company with FDA-cleared technology.

Broad incumbents

  • Preventice Solutions (Boston Scientific): Preventice, now part of Boston Scientific, provides ambulatory ECG and cardiac monitoring services, competing with Prolaio's wearable-based continuous monitoring but operating as part of a much larger device and services portfolio.
  • Philips (BioTel / Cardiac Monitoring): Philips offers cardiac monitoring, ECG, and clinical research services through its connected care and BioTel heritage businesses. It competes with Prolaio in continuous ambulatory monitoring and clinical trial support, but as one segment within a broad medtech portfolio.
  • Tempus Labs: Tempus provides AI-driven precision medicine data and analytics infrastructure to pharma and providers, including for clinical trial design and real-world evidence. It overlaps with Prolaio's platform as a clinical intelligence layer for pharma-sponsored research, though across multiple therapeutic areas.
  • Verily (Alphabet): Verily builds clinical research platforms, wearable sensors, and real-world evidence infrastructure for life sciences companies. It competes with Prolaio in continuous wearable data and clinical trial analytics, backed by Alphabet-scale resources.
  • Hillrom / Baxter (Bardy Diagnostics heritage): Bardy Diagnostics (acquired by Hillrom, now part of Baxter) developed the CAM patch for continuous ambulatory ECG, directly overlapping with Prolaio's ECG patch-based continuous monitoring technology.

Emerging players

  • CardioSignal: CardioSignal develops smartphone- and wearable-based AI analytics for cardiac function, with overlapping technology approach to Prolaio's continuous monitoring and Digital Twin-style analytics, though earlier stage and more consumer-facing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Prolaio social profiles

Digital presence

Prolaio compliance and trust

Trust signal

Compliance4 records

Prolaio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Prolaio leadership team

Management profile

Number of profiles

Profiles11 records

Prolaio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Prolaio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prolaio

What does Prolaio do?

Prolaio provides a cardiovascular clinical intelligence platform that integrates continuous high-density data from clinical-grade wearable sensors with proprietary AI-based algorithms. The platform supports pharmaceutical and biotech companies conducting cardiovascular clinical trials through patient identification, enrollment optimization, real-world evidence generation, and predictive analytics. Key capabilities include FDA-cleared algorithms such as eVO2peak and a Digital Twin machine-learning technology for predicting heart-failure decompensation.

Is Prolaio a public or private company?

Prolaio is a private company. It is classified as corporate owned and is currently acquired.

When was Prolaio founded?

Prolaio was founded in 2022. It employs 51 to 100 people.

Where is Prolaio based?

Prolaio is headquartered in Chicago, United States, in the North America region.

How does Prolaio make money?

Three revenue lines are on record. Clinical Research Services are the primary driver. The others are platform Access for Researchers and data and Analytics Licensing.

Who are Prolaio's main competitors?

Direct peers on record are iRhythm Technologies, AliveCor, Eko Health and HeartFlow. Broad incumbents are Preventice Solutions (Boston Scientific), Philips (BioTel / Cardiac Monitoring), Tempus Labs, Verily (Alphabet) and Hillrom / Baxter (Bardy Diagnostics heritage). CardioSignal is listed as an emerging player.

Does Prolaio have an API?

No public API is recorded for Prolaio.

What industry is Prolaio in?

Prolaio's product category is Cardiovascular Clinical Intelligence Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLALAGAB, Cardiology Telemedicine Platforms. Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Built In ChicagoWhy Employees Recommend Working at Prolaio and SRAMLeah Pozen and Pier Tansey, employees at SRAM and Prolaio, describe their workplaces as people-first and mission-driven. Prolaio's survey shows 94% of employees are proud to work there, while SRAM's 76% of employees support work-life balance. SRAM is moving into a new Chicago office in 2027.BioSpaceKardigan Acquires Prolaio to Create a Pioneering Heart Health Company with One-of-a-Kind Integrated Cardiovascular Data and Therapeutics PlatformKardigan, a heart health company based in South San Francisco and Princeton, has acquired Prolaio, a Chicago-based clinical intelligence company specializing in cardiovascular data and patient monitoring software. The acquisition gives Kardigan access to one of the industry's largest curated CV clinical datasets, FDA-cleared algorithms, and advanced analytics, which the company says could optimize and accelerate its cardiovascular drug development pipeline at reduced cost. Cardiovascular disease is cited as the number one cause of death worldwide, with current standards of care failing to adequately address the growing health crisis.KardiganKardigan Acquires Prolaio to Create a Pioneering Heart Health Company with One-of-a-Kind Integrated Cardiovascular Data and Therapeutics PlatformKardigan acquired Prolaio, a clinical intelligence company, to integrate Prolaio's cardiovascular data and analytics platform. The combination gives Kardigan access to one of the largest curated CV clinical data sets, aiming to accelerate its late-stage CVD assets. Prolaio will continue operating independently as a CV-focused technology company.Built In22 Health Apps to KnowThe article profiles two health apps: Prolaio, a heart health platform integrating with wearables and ECG patches, and Noom, a behavioral-change app with coaching. Both are hiring, and the piece notes the broader growth of health apps during the pandemic.FinSMEsKardigan Acquires ProlaioKardigan acquired Prolaio, a clinical intelligence company, for an undisclosed amount. The deal gives Kardigan access to Prolaio's cardiovascular data collection and analytics platform. Prolaio will continue operating independently as a CV-focused technology company.citybizKardigan Acquires ProlaioKardigan acquired Prolaio, a clinical intelligence company, to integrate its FDA-cleared patient monitoring software and curated cardiovascular data. The combination aims to accelerate Kardigan's late-stage CVD assets and reduce development costs. Prolaio will continue operating independently as a CV-focused technology company.Business Wire BlogKardigan Acquires Prolaio to Create a Pioneering Heart Health Company with One-of-a-Kind Integrated Cardiovascular Data and Therapeutics PlatformKardigan acquired Prolaio, a clinical intelligence company, to integrate Prolaio's FDA-cleared patient monitoring software and cardiovascular data analytics into its R&D pipeline. The combined platform aims to accelerate development of Kardigan's late-stage cardiovascular assets, with Prolaio continuing as an independent CV-focused technology company.SecSEC FORM DProlaio, Inc. filed a Form D with the Securities and Exchange Commission to report an exempt offering of equity securities under Rule 506(b). The filing indicates that the company has sold $25,499,985 USD in securities to three investors as of July 14, 2023.